Literature DB >> 7267186

Assessments of the sensitivities of cultured human neuroblastoma cells to anti-tumour drugs.

B T Hill, R D Whelan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7267186     DOI: 10.1203/00006450-198108000-00009

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


× No keyword cloud information.
  7 in total

1.  Implications for clinical pharmacodynamic studies of the statistical characterization of an in vitro antiproliferation assay.

Authors:  L M Levasseur; H Faessel; H K Slocum; W R Greco
Journal:  J Pharmacokinet Biopharm       Date:  1998-12

2.  9-cis retinoic acid--a better retinoid for the modulation of differentiation, proliferation and gene expression in human neuroblastoma.

Authors:  P E Lovat; H Irving; A J Malcolm; A D Pearson; C P Redfern
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

3.  Phase I and II study of AMSA in childhood tumours.

Authors:  A Goldman; J S Malpas
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Use of human neuroblastoma continuous cell lines for in vitro drug sensitivity screening.

Authors:  B T Hill; R D Whelan; L K Hosking
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850

5.  Uptake and release of iodine-labelled m-iodobenzylguanidine in a neuroblastoma cell culture system and its importance in neuroblastoma therapy.

Authors:  V Paffenholz; U Ebener; B Kornhuber
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

6.  Comparison of the cytotoxic activities of chemotherapeutic drugs using a human bladder cancer cell line.

Authors:  P J Hepburn; R T Oliver; P A Riley; B T Hill; J R Masters
Journal:  Urol Res       Date:  1985

7.  The British Association for Cancer Research, 23rd annual general meeting. Edinburgh 29--31 March 1982. Abstracts.

Authors: 
Journal:  Br J Cancer       Date:  1982-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.